Site Search
Professionals 101 results
Capabilities 39 results
Practice Area
Our attorneys have extensive experience counseling U.S. and multinational public companies across a range of industries in all aspects of corporate governance, securities, and compliance matters. We advise public companies, boards of directors and their committees, and senior executives on the corporate governance and compliance matters that public companies and their leadership confront—from board structuring and succession planning to shareholder activism and SEC regulation. Drawing on our experience as seasoned counselors, we keep clients abreast of evolving trends and best practices to proactively manage any governance or compliance issues. We have assembled one of the most experienced teams of any law firm in the country that’s counseling public companies.
Practice Area
Our Labor & Employment Practice is one of the largest and most experienced practices among the country’s multi-disciplined law firms. Our attorneys represent global employers of all types and sizes—ranging from the Fortune 100 to privately held startups—often serving as national, regional, or preferred counsel to many of these major employers.
Practice Area
As a firm of choice for many major businesses, we represent employers, fiduciaries, boards of directors, benefit plans, and plan administrators in all aspects of ERISA litigation, including claims relating to fiduciary liability, plan investments, excessive fees, plan qualification, plan termination, reversion of excess assets, retiree medical benefits, severance and employment contract matters, tax liability matters, and retirement and welfare benefit claims.
Experience 84 results
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Insights & News 2,777 results
Webinar
|22 JULY 2025
Join us for an insightful webinar during which Dr. Nicole Lux (of Bayes Business School) and Denis Moscovici and Christopher Puyraimond (both of IEIF) will ‘deep dive’ into key data sets emerging from commercial real estate lending market activity in H1 2025 across Western Europe and the Nordics, with a particular focus on France. Winston partner Aparna Sehgal, in conversation with our presenters and panellists, will look at trends and projections emerging from the information analysed, including what to expect for the rest of 2025. We’ll also look at European debt availability and explore the most pressing financing issues of the day.
Client Alert
|July 16, 2025
|4 Min Read
Transatlantic M&A: What Buyers Should Expect
Although 2025 has so far witnessed significant market turbulence, looking ahead into the second half of the year, many factors appear promising: markets have begun to price-in the impact of tariffs, corporates have historically strong cash positions and private equity buyers are under increasing investor pressure to deploy dry powder.
Competition Corner
|July 15, 2025
|3 Min Read
Colorado recently became the second state, after Washington, to enact the Uniform Antitrust Premerger Notification Act (UAPNA) and establish a general state-level premerger notification requirement.
Other Results 45 results
Site Content
A quiet period, also known as as the ‘pre-filing period,’ is the period that begins on the date an offering commences (often the date that Company retains an investment bank) and ends upon the public filing of the registration statement. It is referred to as the quiet period because of the SEC’s restrictions on publicity about the company and/or promoting its offering.
Site Content
What Is the Cooling-Off Period for an IPO?
The cooling-off period is the period of time between the public filing of a registration statement with the SEC and the date the registration statement becomes effective. During this period, no sales may take place. Written offers may only be made with a prospectus meeting the requirements of Section 10 of the Securities Act. Certain oral offers including roadshow presentations may occur during this time along with testing the waters (TTW) activities with certain potential investors.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)